A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient’s quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate–severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours.
The top 3 manufacturers held about 29.5% of the market share in 2019, while top 5 hold 41.93%.

Market Analysis and Insights: Global and United States Acute Migraine Drugs Market
This report focuses on global and United States Acute Migraine Drugs market.
In 2020, the global Acute Migraine Drugs market size was US$ 1956.9 million and it is expected to reach US$ 3211.7 million by the end of 2027, with a CAGR of 7.3% during 2021-2027. In United States the Acute Migraine Drugs market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Acute Migraine Drugs Scope and Market Size
Acute Migraine Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Acute Migraine Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For United States market, this report focuses on the Acute Migraine Drugs market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in United States.

Segment by Type
Triptans
NSAIDs
Others
The proportion of triptans in 2019 is about 79.59% market share.

Segment by Application
Hospital Pharmacies
Drug Stores
The proportion of hospitals in 2019 is about 62.93%.

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
GSK
Teva
Pfizer
Novartis
Sun Pharma
Grunenthal
Endo Pharmaceuticals
Merck
J & J